Quick answer : Inflammation may contribute to depression in some people, but depression should not simply be described as an inflammatory disease. The immune system and brain communicate continuously, and research has identified inflammatory differences in subsets of patients with depression. At this point, however, no single inflammatory blood test can determine the cause of someone’s depression or reliably predict whether ketamine will work.
For many years, researchers focused on neurotransmitters such as serotonin, norepinephrine, and dopamine to explain depression. We now understand that depression involves a much more complex range of biological processes.
The brain constantly communicates with the immune system, endocrine system, autonomic nervous system, gut, and metabolic system. Inflammatory signaling molecules can influence brain function. Researchers have also found evidence of altered inflammatory activity in some people with depression.
However, inflammation does not explain every case of depression. Instead, the immune system may contribute to the broader biological picture in certain patients.
No. Depression affects people in different ways, and two people with major depressive disorder may have very different underlying biological and psychological factors.
Some patients show signs of increased inflammatory activity, while others do not. Even when a blood test reveals an elevated inflammatory marker, that result does not prove inflammation caused the person’s depression.
Markers such as C-reactive protein (CRP) can rise for many reasons. Obesity, infection, autoimmune disease, smoking, metabolic dysfunction, and other factors can influence these levels.
Clinicians should therefore interpret inflammatory markers in context. A single laboratory result cannot establish that inflammation drives someone’s depression.
Researchers have investigated whether ketamine affects inflammatory pathways alongside its better-known effects on glutamate signaling and neuroplasticity.
Some studies suggest that ketamine may influence several inflammatory pathways. However, human studies have produced mixed findings. Researchers have not yet established inflammatory markers as reliable tools for identifying who should receive ketamine or who will respond to treatment.
This distinction matters for patients who encounter claims that a specific cytokine or blood test can reveal exactly why they feel depressed. Current evidence does not support that level of certainty.
Several factors can influence chronic inflammatory activity, including:
Metabolic dysfunction and obesity
Smoking
Inadequate sleep
Physical inactivity
Chronic medical conditions
Periodontal disease
Certain dietary patterns
Psychological stress can also affect immune function through the body’s stress-response system. These relationships are complex, and each process can influence the others.
A broader health evaluation may help when someone continues to experience depression despite appropriate psychiatric treatment. That assessment can identify modifiable health factors worth addressing, even when clinicians cannot establish them as the direct cause of depression.
Not necessarily. High-sensitivity C-reactive protein (hs-CRP) measures systemic inflammation and can help assess cardiovascular risk. However, it does not diagnose depression.
The value of this test depends on each patient’s medical and metabolic history. Testing makes more sense when the results could meaningfully change the clinical evaluation or treatment plan.
Ordering large panels of biomarkers without a clear clinical question can create confusion. Patients may receive abnormal results that clinicians cannot easily interpret and that do not necessarily improve care.
When someone has tried multiple appropriate treatments without achieving remission, clinicians may need to look beyond the next psychiatric medication.
Depending on the individual, a broader assessment may examine:
Sleep quality and physical activity
Metabolic health and nutrition
Substance use
Chronic medical conditions
Current medications
Hormonal factors
Inflammatory conditions
These factors do not replace evidence-based psychiatric care. Instead, they help clinicians build a more complete picture and identify potentially relevant contributors that might otherwise go unnoticed.
Inflammation appears to play a role in depression for at least some patients. However, no single inflammatory mechanism explains all cases of treatment-resistant depression, and no validated inflammatory test can reliably predict whether ketamine will work.
The more useful approach treats inflammation as one possible part of the interconnected biological processes that affect the brain. When clinically appropriate, evaluating those processes in context can help clinicians make more informed treatment decisions.
Inflammatory processes may contribute to depressive symptoms in some people, but the relationship is complex. An association between inflammation and depression does not mean inflammation is the sole cause of someone’s symptoms.
Common clinical markers include CRP or hs-CRP and ESR. These tests are nonspecific and need to be interpreted alongside symptoms, medical history, medications, metabolic health, and other clinical information.
Research suggests ketamine can influence inflammatory pathways, but these findings remain under investigation. Inflammatory biomarkers are not currently validated as a stand-alone method for predicting whether an individual patient will respond to ketamine.
